Hookipa Pharma Inc (NASDAQ: HOOK) on Friday, plunged -4.92% from the previous trading day, before settling in for the closing price of $0.78. Within the past 52 weeks, HOOK’s price has moved between $0.41 and $1.14.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 26.65% over the last five years. The company achieved an average annual earnings per share of 66.57%. With a float of $77.61 million, this company’s outstanding shares have now reached $96.55 million.
The firm has a total of 151 workers. Let’s measure their productivity.
Hookipa Pharma Inc (HOOK) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Hookipa Pharma Inc is 21.56%, while institutional ownership is 37.48%. The most recent insider transaction that took place on Aug 21 ’23, was worth 5,075. In this transaction Chief Financial Officer of this company bought 7,000 shares at a rate of $0.72, taking the stock ownership to the 43,092 shares. Before that another transaction happened on Aug 16 ’23, when Company’s Chief Financial Officer bought 8,000 for $0.71, making the entire transaction worth $5,712. This insider now owns 36,092 shares in total.
Hookipa Pharma Inc (HOOK) Recent Fiscal highlights
As on 3/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.22 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.21) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 66.57% per share during the next fiscal year.
Hookipa Pharma Inc (NASDAQ: HOOK) Trading Performance Indicators
Hookipa Pharma Inc (HOOK) is currently performing well based on its current performance indicators. A quick ratio of 4.50 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.53, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.65 in one year’s time.
Technical Analysis of Hookipa Pharma Inc (HOOK)
Analysing the last 5-days average volume posted by the [Hookipa Pharma Inc, HOOK], we can find that recorded value of 0.37 million was lower than the volume posted last year of 0.73 million. As of the previous 9 days, the stock’s Stochastic %D was 14.67%. Additionally, its Average True Range was 0.07.
During the past 100 days, Hookipa Pharma Inc’s (HOOK) raw stochastic average was set at 34.94%, which indicates a significant increase from 12.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.58% in the past 14 days, which was lower than the 85.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8214, while its 200-day Moving Average is $0.6826. Now, the first resistance to watch is $0.7808. This is followed by the second major resistance level at $0.8181. The third major resistance level sits at $0.8485. If the price goes on to break the first support level at $0.7131, it is likely to go to the next support level at $0.6827. Now, if the price goes above the second support level, the third support stands at $0.6454.
Hookipa Pharma Inc (NASDAQ: HOOK) Key Stats
Market capitalization of the company is 73.57 million based on 98,950K outstanding shares. Right now, sales total 20,130 K and income totals -81,580 K. The company made 36,600 K in profit during its latest quarter, and 14,380 K in sales during its previous quarter.
